Annual Securities Report — FY2025
What ADR Biomedical Holdings Inc. reported for the period from 2025-04-01 to 2026-03-31. Filed by 株式会社ＡＤＲ１２０Ｓ
Filed 2026-06-26View the original on EDINET
How much it says
58Typical
What moved here
17named for the first time
Its own wording
33terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The Group is concentrating on its Medical Business. Due in part to a change in the timing of revenue recognition during the transition to domestic production of the Cellution centrifuge and Cell Therapy Kit, revenue declined for the current consolidated fiscal year, and the Group recorded an operating loss and an ordinary loss. It also received financial support from HG Capital, including the transfer of fixed assets, including trust beneficiary interests, debt forgiveness and the maintenance of a commitment line.
Komori's summary of this document, not the document's own words.58Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
77
Very detailed
94
Very detailed
50
Typical
15
Almost nothing
68
Detailed
55
Typical
62
Detailed
7
Almost nothing
55
Typical
50
Typical
R&D spend2億円Money spent making new things.
Cash left over22億円Cash from the business, less what went into equipment.
Spent on equipment8百万円Plants, machines — things meant to last.
Employees3Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.